Real world experiences of using LIVTENCITY▼® (maribavir)
Clinicians share and discuss their experiences of using LIVTENCITY
Featured in this video:
• Prof Karl Peggs (Professor of Transplant Science and Cancer Immunotherapy, University College London Hospitals)
• Dr Mark Harber (Consultant Nephrologist with Special Interest in Transplantation, Royal Free Hospital)
• Dr Adnan Sharif (Consultant Nephrologist with Special Interest in Transplantation, University Hospitals Birmingham)
• Mr Colin Wilson (Consultant Transplant and Hepatobiliary Surgeon, Newcastle Hospitals)
A case study presentation of managing post-transplant CMV
Featured in this video:
• Dr Mark Harber (Consultant Nephrologist with Special Interest in Transplantation, Royal Free Hospital)
Book a meeting
Click this link to discuss the information on this page further with a Takeda representative.
You might be interested in
article

A summary of the safety profile of LIVTENCITY, including adverse event data and tolerability findings from clinical studies.
article

CMV is one of the most common infections experienced by transplant recipients
article

An overview of the pivotal Phase 3 SOLSTICE trial, outlining the study design, patient population, and methodology that underpin the clinical evidence for LIVTENCITY.